23 06, 2020

Brain cancer testing without the invasive biopsy from @decarvalho_lab

By | June 23rd, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics|0 Comments

Brain cancer is difficult to diagnose and stratify without an invasive biopsy. Daniel De Carvalho’s group have used their cfChIP-Seq technology to non-invasively diagnose and classify brain tumours, potentially removing the need for surgical tissue biopsies. The power of the assay comes from its use of […]

18 06, 2020

Tumour-informed sequencing to increase the sensitivity of ctDNA liquid biopsy

By | June 18th, 2020|Categories: ctDNA, Diagnostics Tech, MRD|0 Comments

A new paper from Nitzan Rosenfeld’s group at CRUK-CI (my old stomping ground) reports astounding sensitivity for ctDNA liquid biopsy. In “ctDNA monitoring using patient-specific sequencing and integration of variant reads” Jonathan Wan and his co-authors performed whole exome sequencing on tumour biopsies (and PBMCs) […]

5 06, 2020

Avida Biomed: early cancer detection with methylation

By | June 5th, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics, MRD|0 Comments

Avida Biomed are an early startup who have developed a novel targeted methylation sequencing technology: Point-n-Seq, for cancer early-detection. Point-n-Seq uses targeted methylation sequencing, which performs enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Target panels are small 1-1000 markers. The […]

18 03, 2020

A CRISPR diagnostic for Covid-19 from @mammothbiosci

By | March 18th, 2020|Categories: Diagnostics Tech, Other stuff|0 Comments

Mammoth Biosciences, one of the two companies developing CRISPR as a diagnostic tool, submitted a medRxiv preprint showcasing their work on a Covid-19 assay. The SARS-CoV-2 DETECTR assay generate results in 30 minutes from from extracted patient sample RNA. The assay performs simultaneous reverse transcription […]

27 11, 2019

Evidence for the use of cfDNA Fragmentome for early detection and monitoring of cacner

By | November 27th, 2019|Categories: Diagnostics Tech, Methods and applications, Next-generation sequencing|0 Comments

In Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection researchers at the Institute of Human Genetics in Austria demonstrate the use of cfDNA for cancer detection and monitoring. The group performed deep ATAC-Seq and deep cfDNA nucleosome mapping to […]

18 04, 2019

#CRISPR Diagnostics part 2

By | April 18th, 2019|Categories: Diagnostics Tech, Methods and applications, Uncategorized|Tags: , |0 Comments

#CRISPR diagnostics got even more exciting with two big announcements last month. Firstly, Sherlock Biosciences, has spun out from The Broad Institute and Wyss Institute commercialising the SHERLOCK and INSPECTR technologies (I’ll be covering the battle for CRISPR Dx dominance in this post). Secondly, researchers at […]

15 05, 2018

Nanostring in Cambridge

By | May 15th, 2018|Categories: Diagnostics Tech, Methods and applications, Next-generation sequencing|0 Comments

On Friday last week I had the pleasure of hosting a half-day Nanostring symposium at Cancer Research UK’s Cambridge Institute (my previous employer). The symposium was arranged as an opportunity to get Nanostring users, and potential users, together to hear about the exciting developments in […]

1 05, 2018

Biotin health supplements may affect lab tests

By | May 1st, 2018|Categories: ctDNA, Diagnostics Tech, Methods and applications, Other stuff|0 Comments

The FDA issued a safety communication today on the risk that biotin supplements “can significantly interfere with certain lab tests and cause incorrect test results”. The FDA communiqué mentions an increase in reported adverse events, and even one death, because of Biotin interference. Biotin interferes with some […]

Load More Posts